Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
Authors Zhang J, Li J, Zhu C, Song Y, Xia F, Ma X
Received 13 August 2017
Accepted for publication 20 October 2017
Published 15 November 2017 Volume 2017:11 Pages 3235—3244
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Qinghua Deng
Peer reviewer comments 2
Editor who approved publication: Dr Georgios Panos
Jing Zhang,1,2,* Jinying Li,3 Chenjing Zhu,1 Yanlin Song,1 Fan Xia,1 Xuelei Ma1,*
1Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy, 2Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 3The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao Central Hospital, Qingdao, People’s Republic of China
*These authors contributed equally to this work
Background: The aim of this review was to systematically evaluate the safety and efficacy of the addition of pertuzumab to trastuzumab emtansine (T-DM1) ± taxane in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).
Materials and methods: Several databases were searched for relevant clinical trials. The study characteristics, details of adverse events (AEs) and details of treatment efficacy were extracted for analysis.
Results: Six studies with 996 patients were included. Common AEs of T-DM1 + pertuzumab ± taxane included fatigue, diarrhea, nausea, epistaxis, peripheral neuropathy, increased aspartate transaminase (AST), increased alanine transaminase (ALT) and thrombocytopenia. Major grade ≥3 AEs of T-DM1 + pertuzumab ± taxane included thrombocytopenia, neutropenia, fatigue, increased ALT, anemia and peripheral neuropathy. The addition of pertuzumab to T-DM1 ± taxane led to higher risks of diarrhea (especially grade ≥3 diarrhea), rash and vomiting, and decreased risks of thrombocytopenia and grade ≥3 increased AST. The relative risks of the addition of pertuzumab to T-DM1 ± taxane for objective response (1.068, 95% CI 0.945–1.207) and clinical benefit (1.038, 95% CI 0.974–1.106) were not statistically significant.
Conclusion: Common AEs should be carefully monitored in HER2-positive LABC or MBC patients treated with T-DM1 + pertuzumab ± taxane. The addition of pertuzumab to T-DM1 ± taxane showed noninferior, but not superior, objective response rate and clinical benefit rate. However, more studies are needed to further verify these findings.
Keywords: trastuzumab emtansine, pertuzumab, human epidermal growth factor receptor 2, breast cancer, adverse events, efficacy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]